These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1486 related articles for article (PubMed ID: 22204894)
1. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. Serri J; Legré R; Veit V; Guardia C; Gay AM Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis. Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168 [TBL] [Abstract][Full Text] [Related]
3. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma. Uppal L; Dhaliwal K; Butler PE J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360 [TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study. Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary. Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658 [TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. Fregene A; Ditmars D; Siddiqui A J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141 [TBL] [Abstract][Full Text] [Related]
7. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin A treatment of Raynaud's phenomenon: a review. Iorio ML; Masden DL; Higgins JP Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066 [TBL] [Abstract][Full Text] [Related]
9. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience. Nagarajan M; McArthur P Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A in the treatment of Raynaud's phenomenon. Neumeister MW J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617 [TBL] [Abstract][Full Text] [Related]
11. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Bello RJ; Cooney CM; Melamed E; Follmar K; Yenokyan G; Leatherman G; Shah AA; Wigley FM; Hummers LK; Lifchez SD Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903 [TBL] [Abstract][Full Text] [Related]
12. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968 [TBL] [Abstract][Full Text] [Related]
13. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series. Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318 [TBL] [Abstract][Full Text] [Related]
14. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma. Colakoğlu M; Cobankara V; Akpolat T Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574 [TBL] [Abstract][Full Text] [Related]
15. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Gore J; Silver R Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356 [No Abstract] [Full Text] [Related]
16. Treatment of Raynaud's phenomenon with botulinum toxin type A. Zhang X; Hu Y; Nie Z; Song Y; Pan Y; Liu Y; Jin L Neurol Sci; 2015 Jul; 36(7):1225-31. PubMed ID: 25616446 [TBL] [Abstract][Full Text] [Related]
17. Management of Raynaud's digital ulcer with interdigital Botulinum toxin A injection. Navarro EP; Cañas CA; Tobón GJ Rheumatology (Oxford); 2016 Jul; 55(7):1216. PubMed ID: 27155203 [No Abstract] [Full Text] [Related]
18. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239 [TBL] [Abstract][Full Text] [Related]
19. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. Abou-Raya A; Abou-Raya S; Helmii M J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692 [TBL] [Abstract][Full Text] [Related]
20. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes. Dhaliwal K; Griffin M; Denton CP; Butler PEM BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]